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Abstract 
The pool of microbes inhabiting our body is known as 
“microbiota” and their collective genomes as “microbi-
ome”. The colon is the most densely populated organ 
in the human body, although other parts, such as the 
skin, vaginal mucosa, or respiratory tract, also harbour 
specific microbiota. This microbial community regulates 
some important metabolic and physiological functions 
of the host, and drives the maturation of the immune 
system in early life, contributing to its homeostasis 
during life. Alterations of the intestinal microbiota can 
occur by changes in composition (dysbiosis), function, 
or microbiota-host interactions and they can be directly 
correlated with several diseases. The only disease in 
which a clear causal role of a dysbiotic microbiota has 
been demonstrated is the case of Clostridium difficile  
infections. Nonetheless, alterations in composition and 
function of the microbiota have been associated with 
several gastrointestinal diseases (inflammatory bowel 
disease, colorectal cancer, or irritable bowel syndrome), 
as well as extra-intestinal pathologies, such as those 
affecting the liver, or the respiratory tract (e.g. , allergy, 
bronchial asthma, and cystic fibrosis), among oth-
ers. Species of Bifidobacterium genus are the normal 
inhabitants of a healthy human gut and alterations in 
number and composition of their populations is one of 
the most frequent features present in these diseases. 
The use of probiotics, including bifidobacteria strains, 
in preventive medicine to maintain a healthy intestinal 
function is well documented. Probiotics are also pro-
posed as therapeutic agents for gastrointestinal disor-
ders and other pathologies. The World Gastroenterol-
ogy Organization recently published potential clinical 
applications for several probiotic formulations, in which 
species of lactobacilli are predominant. This review is 
focused on probiotic preparations containing Bifidobac-
terium strains, alone or in combination with other bac-
teria, which have been tested in human clinical studies. 
In spite of extensive literature on and research into this 
topic, the degree of scientific evidence of the effective-
ness of probiotics is still insufficient in most cases. More 
effort need to be made to design and conduct accurate 
human studies demonstrating the efficacy of probiotics 
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Core tip: In this review we focus on how bifidobacte-
ria can contribute to maintain a proper health status 
through their interactions with gut microbiota and the 
host. We present several gastrointestinal and extra-
intestinal pathologies associated with imbalances in 
the microbiota composition and function, including 
bifidobacteria-associated dysbiosis. We review up-to-
date scientific evidence sustaining the use of probiotic 
bifidobacteria to prevent, or treat, several disorders, 
and we include a list of specific Bifidobacterium  strains 
that have been tested in human clinical studies.
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INTRODUCTION
About 100 trillion (1014) microbes inhabit the human 
gut, which represents 10 fold the number of  eukaryotic 
cells in the body and contributes 1.5-2 kg of  total body 
weight[1]. The number and complexity of  these microbial 
populations gradually increase from the stomach to the 
colon, where microorganisms reach levels of  up to 1011 
cells per gram of  intestinal content[2]. Although the colon 
is the more densely populated organ, microorganisms 
are also normal inhabitants of  other parts of  the body, 
such as the skin, vagina, throat and the upper respiratory 
tract[3]. This pool of  microbes is known as “microbiota” 
and the ensemble of  their genes is named “microbiome”. 
Microbiota composition
The recent advent of  next generation sequencing tech-
niques has greatly contributed to demonstrate that the 
human body harbours more than 1000 phylotypes at 
species-level, but most intestinal bacteria belong to just 
a few phyla. In adults, Bacteroidetes and Firmicutes usually 
dominate the intestinal microbiota, whereas Actinobacteria, 
Proteobacteria and Verrucomicrobia are in considerably minor 
proportion (Figure 1). Methanogenic archaea (represented 
by Methanobrevibacter smithii), eukaryotes (mainly yeast) and 
viruses (mainly bacteriophages) are also components of  
this microbiota[3,4]. A recent work identified three entero-
types in the human gut microbiome differing in species 
and functional characteristics[5]. In spite of  a consistency 
in the global composition, the intestinal microbiota seems 
to be highly variable among individuals at species-level 
phylotypes; usually Faecalibacterium prausnitzii (F. prausnit-
zii), Roseburia intestinalis, Bacteroides uniformis, and species 
of  bifidobacteria and lactobacilli are present in most 
people[6]. The microbial colonization of  the gut begins 
in infants immediately after birth. Facultative anaerobes, 
such as enterobacteria, enterococci and lactobacilli are the 
first colonizers (Figure 1). Anaerobic microorganisms, in-
cluding Bifidobacterium, Bacteroides and Clostridium establish 
gradually, and contribute to a progressive decrease of  the 
facultative anaerobes to strict anaerobes ratio in time[7]. 
At about 3 years of  age, the gut microbiota reaches a 
composition and diversity similar to adults and remains 
more or less stable over time in adulthood. New changes 
appear in the senescence, the microbiota of  elderly peo-
ple differing from the core microbiota and diversity levels 
of  younger adults[8,9].  
Microbiota function
Gut microbiota provides nutrients and energy for the 
host through the fermentation of  non-digestible dietary 
components in the large intestine. The main products of  
the substrate fermentation in the gut are short chain fatty 
acids (SCFA), which interact with the intestinal microbi-
ota and host cells. The microbiota regulates, via different 
mechanisms, some important physiological functions of  
the host, such as those related to energy expenditure, sa-
tiety and glucose homeostasis[10,11]. It can also act as a bar-
rier against the establishment of  foodborne pathogens. 
Remarkably, the intestinal microbiota is also in contact 
with the second largest (after the brain) neural pool of  
cells in the body, as well as with the largest group of  im-
mune cells in our organism[12]. Therefore, the microbiota 
drives the maturation of  the immune system in infancy 
and contributes to the maintenance of  its homeostasis 
during life[13,14]. Moreover, the possible influence of  the 
microbiota in the development of  the nervous system 
and in cognitive function currently constitutes a hot tar-
get for biomedical research[15].
Factors affecting microbiota
Some external and internal factors of  the host can in-
fluence the composition and metabolic activity of  the 
intestinal microbiota. Diet strongly affects human health, 
partly through its interaction with intestinal microbiota[16]. 
Distinctive features have been clearly evidenced recently 
across different geographic locations, which can be partly 
explained by differing diets[17]. Functional immaturity 
of  the immune system and intestinal epithelium can 
influence the aberrant intestinal colonization pattern oc-
curring in preterm neonates[18]. The type of  feeding in 
early infancy (breast-fed vs formula fed) also seems to 
condition the microbiota establishment, as well as the 
maturation of  the immune system. Medication, especially 
chronic medication, can exert a strong impact on intesti-
nal microbiota[19]. A misbalance of  this intestinal microbi-
15164 November 7, 2014|Volume 20|Issue 41|WJG|www.wjgnet.com
Tojo R et al . Intestinal bifidobacteria in health and disease
al community can act as a source of  infection, or chronic 
inflammation, and can be involved, as well, in gastrointes-
tinal diseases and other extra-intestinal disorders.
MICROBIOTA AND GASTROINTESTINAL 
PATHOLOGY
As the gut microbiota has a well-established role in host 
homeostasis, several highly prevalent gastrointestinal 
diseases have been associated with shifts, or imbalances, 
in microbiota composition (dysbiosis) and function, as 
well as in microbiota-host interactions[20,21]. The term 
dysbiosis is unhelpful if  used only to describe a change 
in the microbiota, which is assumed to be deleterious to 
the host. In some instances, changed microbiota may be 
an appropriate response to a change in the host, or may 
represent an epiphenomenon without pathophysiologi-
cal implications[22]. Therefore, as the entire functional 
complexity of  the gut microbiota is incompletely defined, 
with just a determination of  composition by taxonomic 
assignment[6], a functional analysis may provide informa-
tion about metabolic and immunologic functions, as well 
as microbiota-host interactions[23]. 
Clostridium difficile infection 
The only disease process in which a dysbiotic microbiota 
plays an undoubtedly proven role is in the case of  Clos-
tridium difficile infection (CDI). Treatment with antibiotics 
transiently alters the microbiota composition, providing 
the niche in which this pathogen can expand[20]. The res-
toration of  normal healthy microbiota, by faecal microbi-
ota transplantation (FMT) is an effective therapy to treat 
CDI[24]. FMT consists of  the engraftment of  microbiota 
from a healthy donor(s) into a recipient, which results in 
the restoration of  the normal gut microbial community 
structure, with the aim of  recovering metabolic and im-
munologic balance[25]. FMT introduces a complete, stable, 
and durable community of  gut microbiota[26], unlike 
probiotics, that temporarily alter the metabolic, or im-
munologic activity, of  the native gut microbiota[27]. The 
mechanism(s) that facilitates this microbiota normaliza-
tion, as well as the occurrence of  putative long-term side 
effects, still has to be determined. However, FMT rep-
resents an emerging therapy for disease states related to 
dysbiosis, and is a current, recommended treatment for 
relapsing and non-responding CDI[28].  
Inflammatory bowel diseases 
There is increasing evidence of  the pathogenic implica-
tion of  the host microbiota in inflammatory bowel dis-
ease (IBD), as several taxonomic and functional changes, 
as well as imbalances in the host-microbiota cross-talk, 
have been described[29]. This may be understood as a bi-
directional relationship between altered immune function 
(mucosal barrier, innate bacterial killing, or immune regu-
lation) and altered bacterial community (its features, func-
tions, or metabolites)[30]. A deregulated immune response 
against commensal gut bacteria, in which local tolerance 
mechanisms towards commensal microbes seem to be 
impaired, may contribute to the onset or perpetuation 
of  IBD[31]. Studies of  faecal and gut mucosal-associated 
microbiota have demonstrated quantitative and qualita-
tive changes in composition and function associated with 
IBD, with a shift towards an inflammatory-promoting 
microbiome[32]. There is a decreased complexity in com-
position, with a loss of  normal anaerobic bacteria[33], a 
temporary composition instability during clinical remis-
sion[34], and a dysbiosis towards selected microorganisms, 
with over- and under-representation of  certain species[35]. 
An excessive abundance of  Desulfovibrio species has been 
described in ulcerative colitis (UC), which has pathogenic 
potential due to its ability to generate sulfides[36]. In ad-
dition, an increase in microbial genes involved in the 
metabolism of  cysteine (sulphur-containing amino acid) 
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Figure 1  Evolution of some representatives of the intestinal microbiota accordingly to age.
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categorized based upon clusters of  chronic, or recurrent 
symptoms that can be attributed to the gastrointestinal 
tract in the absence of  any discernible organic abnor-
mality[50]. An increasing body of  evidence supports the 
physio-pathological role of  microbiota in irritable bowel 
syndrome (IBS), although the clinical relevance of  many 
findings still remains unclear[51]. Clinical studies show 
that up to 20% of  IBS is preceded by an enteric infec-
tion, which produces a profound alteration of  the host 
microbiota[52]. The precise mechanisms by which this 
alteration determines the persistency of  IBS symptoms 
after the acute episode are not fully elucidated; a genetic 
susceptibility, an abnormal mucosal barrier integrity, 
variations in SCFA production, and an increase in mu-
cosal entero-endocrine cells may contribute[53,54]. A meta-
analysis review showed that small intestinal bacterial 
overgrowth (SIBO) was present between 4% and up to 
54% in IBS[55], suggesting that microbiota alterations may 
play a role in a subset of  patients. However, the large dif-
ferences between the studies, methodological problems, 
such as the lack of  standardization, poor sensitivity and 
specificity of  breath tests, as well as the questioned cut-
off  value of  cultured duodenum/jejunum aspirates (> 
105 CFU/mL), make the importance of  SIBO in IBS 
unclear[56]. Interventional studies showing the positive 
effects of  treatments directed at gut microbiota also sup-
port the role of  microbial alterations in IBD[57,58]. Indeed, 
several alterations in microbiota composition have been 
described, although the heterogeneity of  IBS, as well 
as methodological variations, has resulted in contradic-
tory reports. Nonetheless, emerging data support the 
existence of  dysbiosis in a subset of  IBS[59]: a decreased 
complexity in composition[60], temporary instability[61], 
and changes in the mucosa-associated microbiota, with 
an increase in Bacteroides and Clostridia and a reduction in 
Bifidobacterium[62]. 
There are several functional changes that may con-
tribute to the pathophysiology of  IBS. An altered fer-
mentation process, with an increase in faecal SCFA and 
their producing bacteria, has been described; the highest 
levels being related to the severest symptoms[63]. The al-
teration of  intestinal barrier function, with increased gut 
permeability, has a major role in IBS[64]; nevertheless, its 
relationship with altered microbiota remains to be fully 
understood. Modulation of  enteric sensorimotor func-
tion, through alterations in bile acid metabolism by mi-
crobiota, has been described in several in vitro studies[59]. 
An increase in primary bile acids in faeces, associated 
with the decrease in C. leptum (able to transform primary 
into secondary bile acid), was correlated with the stool 
consistency in diarrhoea predominant IBS[65]. There is a 
growing appreciation for the hypothesis that IBS may be 
a condition of  low-grade inflammation without strong 
tissue damage, but enough to alter the sensorimotor 
function and produce symptoms[66]. However, there are 
few studies assessing a direct link between alterations in 
gut microbiota and low-grade inflammation or immune 
activation in the gut. Finally, data from animal and human 
studies have demonstrated the effects on the brain-gut 
and sulphate transport systems have been reported[37]. 
UC and Crohn´s disease (CD) present a low abundance 
of  F. prausnitzii, which has known anti-inflammatory 
properties[38], and this is associated with a higher risk of  
postoperative recurrence of  ileal disease[29], and with a 
concomitant increase in the abundance of  Escherichia coli 
(E. coli)[39]. Adherent-invasive E. coli strains are specifically 
associated with the CD ileal phenotype[40]. In addition, a 
decrease of  SCFA levels, and of  genes related to SCFA 
metabolism, is described in CD[41]. Clinical and basic 
evidence suggests that dysbiosis has a key role in the ini-
tiation and progression of  chronic inflammation in the 
pouch reservoir[29]. A notable increase in Proteobacteria (E. 
coli and other enterobacteria), with a marked decrease in 
Bacteroides and F. prausnitzii, has been described[42].  
Colorectal cancer 
There is a strong genetic component in the development 
of  colorectal adenomas and colorectal cancer (CRC), 
but there are also environmental factors linked to this 
disease[43]. Considering the continuous exposure of  the 
colonic mucosa to the microbiota and its metabolites, this 
microbial community has been proposed as contributing 
to carcinogenesis. However, the mechanisms of  this asso-
ciation remain unknown, although there are several ways 
in which an altered microbiota may promote CRC[44]. 
Chronic intestinal inflammation has been associated with 
the development of  CRC and it can result from an aber-
rant ratio of  protective (tolerogenic) to aggressive (pro-
inflammatory, pro-tumorigenic) microbiota[45]. In this 
regard, Bacteroides fragilis (B. fragilis) and Streptococcus bovis 
(S. bovis) could be linked to the development of  CRC by 
activating immune cells to release pro-mitogenic and pro-
angiogenic cytokines, mostly Interleukin-17 (IL-17)[46]. 
There are also some biological activities of  the intestinal 
microbiota that are presumed to generate metabolites 
involved in CRC carcinogenesis: secondary bile salt 
transformations, desulfuration of  bile acids, production 
of  hydrogen sulfide, production of  aglycones from inac-
tivated harmful compounds, bacterial β-glucuronidases, 
production of  aromatic amines by azoreductases and ni-
troreductases, generation of  acetaldehyde, and generation 
of  reactive oxygen species[47].
Several changes in microbiota composition are de-
scribed in CRC. An increased diversity in Clostridium 
leptum (C. leptum) and Clostridium coccoides is present, while 
temporary instability and decreased complexity in com-
position are linked to colitis-associated CRC[48,49]. The 
microenvironment within colorectal neoplastic lesions is 
significantly different from normal intestine, thus it can 
promote the accumulation of  additional mutations and 
epigenetic changes. Many bacterial species were found to 
be enriched in colorectal tumour samples and adjacent 
tissue: B. fragilis, Bacteroides vulgatus, Bifidobacterium longum, 
Clostridium butyricum, Mitsuokella multiacida, E. coli, Enterococ-
cus faecalis, and S. bovis[45]. 
Functional gastrointestinal disorders 
Functional gastrointestinal disorders are defined and 
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axis at peripheral and central levels, with an impact on the 
enteric nervous system, brain chemistry and behaviour[67]; 
although caution must be exercised when in speculating 
on the implications of  these findings[68]. 
MICROBIOTA AND EXTRA-INTESTINAL 
PATHOLOGY
It has been denoted that aberrancies in intestinal micro-
biota may be involved in intestinal diseases. Moreover, 
there is increasing evidence that dysbiosis in this micro-
bial community could be related with some extra-intes-
tinal pathologies, such as allergies, obesity and metabolic 
syndrome, rheumatic disease, and degenerative processes, 
among others[69-71]. 
Liver diseases
Modifications in intestinal microbiota have been associ-
ated with the physiopathology of  non-alcoholic fatty 
liver disease (NAFLD), alcoholic liver disease, and total 
parenteral nutrition-intestinal failure liver disease, as well 
as in the precipitation of  infectious and non-infectious 
complications of  liver cirrhosis[72]. Among the potential 
contributors of  the microbiota to complications of  liver 
cirrhosis is the presence of  SIBO[73], and a dysfunctional 
mucosal barrier which can contribute to bacterial (or 
endotoxin) translocation to the portal circulation[74]. The 
pivotal role of  gut microbiota in the pathogenesis of  he-
patic encephalopathy is supported by interventional stud-
ies showing the positive effects of  treatments directed at 
gut microbiota in primary prophylaxis[75]. Gut microbiota 
is also involved in the pathogenesis of  NAFLD and its 
progression to non-alcoholic steatohepatitis. In obese 
patients, the accumulation of  triglyceride-derived me-
tabolites in the liver is due to an increased release of  fatty 
acids from dysfunctional and insulin-resistant adipocytes. 
A specific microbial taxonomic and functional profile has 
been associated with obesity[76] and obesity-related liver 
disease[77], thus suggesting a link between microbiota and 
liver pathology[78].
Respiratory diseases 
The relationship between intestinal microbiota and 
chronic respiratory diseases is poorly understood. How-
ever, a few works have been able to establish a connec-
tion between an aberrant microbiota, allergic diseases 
and bronchial asthma. Several epidemiological studies 
have shown a clear inverse link between early exposure to 
microorganisms and the incidence of  asthma, referring 
to this phenomenon as the “hygiene hypothesis”[79]. Also, 
the increased use of  antibiotics and changes in dietary 
patterns in developed countries, may lead to alterations in 
the composition of  the intestinal microbiota and a higher 
risk of  bronchial asthma[80-82]. Thus, a reduction of  Bacte-
roidetes, lactobacilli and bifidobacteria has been associated 
with an asthma phenotype[83]. Recent research, focused 
on the study of  airway microbiota and their potential 
consequences in asthmatic patients, shows that biodiver-
sity is much higher in asthmatic patients with bronchial 
hyper-reactivity compared with healthy subjects[84].
The results of  some studies on other chronic respira-
tory diseases suggest that pulmonary inflammation and 
intestinal inflammation are somehow related to each 
other, and both contribute to the progression of  chronic 
lung disease. This relationship is more evident in some 
diseases such as cystic fibrosis (CF), in which the lung 
and intestinal habitats are interconnected through a lung- 
intestine axis. Evidence suggests that in CF patients the 
lung disease determines the vital prognosis[85]. CF is an 
autosomal recessive genetic disease caused by mutations 
in the gene coding for the regulatory transmembrane 
conductance regulator (CFTR), which results in progres-
sive lung disease, pancreatic insufficiency, and deficiencies 
in growth and nutrition. CFTR functions as a chloride 
ion channel that controls the transportation of  water and 
ions across the apical membrane of  epithelial cells. There 
are different genetic mutations, responsible for different 
degrees of  severity, the DF508 mutation being associated 
with the most serious symptoms, and one of  the most 
common ones. In this sense, the results of  a recent study 
have shown that the composition of  the intestinal micro-
biota in patients with CF is significantly different depend-
ing on the genetic variation[86]; patients with the DF508 
mutation have a marked intestinal dysbiosis, in which 
harmful species, such as E. coli and Eubacterium biforme, 
are abundant, whereas potentially beneficial ones, such as 
F. prausnitzii and Bifidobacterium spp., are decreased[86]. In 
general, these patients, regardless of  their genetic back-
ground, display a permanent dysbiosis, motivated in part 
by the characteristics of  the disease (thick mucus secre-
tion and pancreatic insufficiency) and the effect related 
to the aggressive antibiotic therapy[87]. Moreover, it is 
important to try to correlate the alterations of  the airway 
microbiota with alterations in intestinal microbiota in 
CF patients. Some authors suggest a link between nutri-
tion and the development of  microbial communities in 
the respiratory tract[88]. These authors note how dietary 
changes give rise to alterations in the microbiota of  the 
respiratory tract, suggesting that nutritional factors and 
the pattern of  intestinal colonization are determining 
microbial growth in the respiratory airways, and giving us 
the opportunity to evaluate the response of  CF patients 
to probiotic and prebiotic interventions[88].
Oral administration of  prebiotics or probiotics, or a 
combination of  both, can lead to a change in the com-
position of  the intestinal microbiota. This can directly 
influence the composition of  the microbial communi-
ties of  the airway by the release of  bacterial products or 
metabolites that reach the lung. These mechanisms could 
theoretically lead to the restoration of  a microbiota that 
promotes a healthy status, thus having a therapeutic ef-
fect on chronic diseases[89]. It is also important to note 
that probiotic treatment may modulate immune response 
in the lung; in particular gut microbial stimulation can en-
hance T regulatory response in the airway, which empha-
sizes the potential role of  probiotics in the pulmonary 
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inflammatory response[89]. However, the mechanisms un-
derlying these specific effects of  probiotics are far from 
being completely understood. Therefore, it will be of  key 
importance to know if  airway microbiota is derived from, 
or linked to, intestinal microbiota. This would mean that 
a modulation of  the intestinal microbiota could have a 
positive effect on lung disease. Considering this, char-
acterization, modification and the possible functional 
consequences of  airway microbiota are emerging fields 
that can constitute a new way of  acting on chronic lung 
diseases.
INTESTINAL BIFIDOBACTERIA
The genus Bifidobacterium belongs to the phylum Actino-
bacteria and comprises over 45 species/subspecies of  high 
G + C (guanine and cytosine) content in their genomes; 
they are gram-positive, polymorphic rod-shaped bacteria 
and normal inhabitants of  the gastro-intestinal tract of  
humans and animals[90]. In the human gut the most com-
monly found species of  Bifidobacterium genus include B. 
adolescentis, B. angulatum, B. bifidum, B. breve, B. catenulatum, 
B. dentium, B. longum, B. pseudocatenulatum, and B. pseudolon-
gum[91], whereas B. animalis subsp. lactis is the species most 
often included in functional foods and food supple-
ments[92]. Bifidobacteria is a dominant microbial group 
in healthy breastfed babies and, during an adult´s life the 
levels remain relatively stable, tending to decrease in the 
senescence[93]. During recent years this genus has been 
extensively studied due to both its important role within 
the human intestinal microbiota and the extensive use of  
certain Bifidobacterium strains in probiotic products. 
As has been highlighted in the previous sections, 
intestinal microbiota dysbiosis has been described in dif-
ferent diseases. Given the attention traditionally paid to 
the genus Bifidobacterium, aberrancies in specific bifidobac-
terial microbiota, such as decreased numbers, or atypical 
species composition, have been identified in some of  
them (Figure 2); these include atopic disease[94,95], IBS[96,97], 
IBD[98-101], CRC[102], or celiac disease[103,104]. Additionally, 
bifidobacteria dysbiosis has been reported to precede 
obesity[105]. It is important to stress that no definitive 
proof  is available on the relationship between reduced 
bifidobacterial levels, or altered species composition, and 
disease. However, an aberrant bifidobacterial number or 
composition is perhaps the most frequently observed in-
testinal microbiota alteration, being present in many dif-
ferent diseases. This fact suggests an important role for 
the bifidobacteria population in the intestinal homeosta-
sis. Therefore, on one hand, the bifidobacteria fingerprint 
could be used as a potential biomarker to understand the 
intestinal status pointing to a putative dysbiosis. On the 
other hand, increasing bifidobacterial levels in the gas-
trointestinal tract could be considered a target to prevent 
and/or alleviate microbiota-associated diseases. In this 
regard, several health-promoting effects have been at-
tributed to some specific strains of  this genus. The use 
of  functional foods towards the oral delivery of  benefi-
cial bifidobacteria (probiotics), alone, or in combination 
with substrates (prebiotics) that promote the growth of  
beneficial microbes in the gut, are the basis of  dietetic 
intervention strategies to amend or attenuate intestinal 
dysbiosis. 
Probiotics were defined in 2001 by a group of  ex-
perts, joined by the World Health Organization and the 
Food Agriculture Organization of  the United Nations, 
as “live microorganisms, which when administered in 
adequate amounts confer a health benefit on the host”[106]. 
However, interest in the use of  living bacteria as thera-
peutic agents started at the beginning of  the 1900s with 
the observations of  the Nobel Prize winner Ellie Metch-
nikoff, and the pediatrician Henry Tissier, both working 
at the Pasteur Institute. Indeed, Tissier detected that 
bacteria with “bifid” shape, which were abundant in the 
faeces of  healthy children, were absent in those suffering 
from diarrhoea; thus he proposed the use of  (bifido)-
bacteria to restore a healthy microbiota[107]. Afterwards, 
the use of  pro-life (probiotic) microorganisms did not 
receive much attention in the scientific community in 
the West. However, around 1930 Dr. Minoru Shirota, 
Balanced Bifidobacteria
(number and composition)
Health
Bifidobacteria dysbiosis
Disease Atopic allergy
IBS, IBD
Colorectal cancer
Celiac disease
Obesity
Probiotic bifidobacteria
Balance restoration
Figure 2  Bifidobacterial dysbiosis and its relationship with diseases: A target for probiotic intervention. IBD: Inflammatory bowel disease; IBS: Irritable bowel 
syndrome.
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working at the Medicine School of  Kyoto, cultured a 
bacterium strain (Lactobacillus casei strain Shirota) that be-
come the first probiotic commercialized in 1935 by the 
Japanese company Yakut[108]. The market for foods con-
taining probiotics, including bifidobacteria, is growing at 
a high rate in recent years. Research on this topic is also 
receiving a lot of  attention, since the use of  probiotics in 
preventive medicine to keep a healthy intestinal function 
is well documented, and probiotics are also proposed 
as therapeutic agents for gastrointestinal disorders and 
other pathologies[27]. 
A search in the Cochrane Library (http://onlineli-
brary.wiley.com/cochranelibrary/search) for research 
into “probiotics” in human health shows several sys-
tematic reviews about the use of  these microorganisms 
for prevention, or treatment, of  several diseases (Table 
1)[109-127]. The overall picture of  these studies indicates 
that the degree of  scientific evidence of  the effective-
ness of  probiotics on several pathologies, mainly gut-
associated diseases, is insufficient, or the data were not 
enough to arrive at a conclusion. In most reviews, the 
selection of  human intervention trials with probiotics 
was a miscellaneous of  studies, without defined criteria: 
probiotic strains were not completely defined (at strain 
level, dose, vehicle of  delivery, duration of  the interven-
tion, etc.); the placebo group was not accurate; often pro-
biotics were used in combination with other therapies 
(e.g., antibiotics); the human target population was not 
clearly delimited (age, physio-pathological state of  the 
disease, etc.); among others. This lack of  definition could 
mask any beneficial findings obtained with probiotics, 
and it could hinder a real progress in obtaining effective 
products. Therefore, more attention should be paid to 
design, conduct and accurate reporting human studies 
on probiotics. 
Bifidobacteria as probiotic in gastrointestinal pathology
In spite of  the above mentioned limitations, the World 
Gastroenterology Organization (WGO) has recently 
published potential clinical applications for several pro-
biotic formulations, in which species of  Lactobacillus play 
a predominant role[128]. In the current review, we have 
compiled a series of  human intervention studies, showing 
beneficial effects in gastrointestinal health, which have 
been made with bifidobacterial strains (Table 2)[129-154]. 
It is worth noting that only a few Bifidobacterium strains, 
such as the case of  B. animalis subsp. lactis HN019 and 
B. infantis 35624, have been studied alone, and not in 
combination with other strains, which limits the conclu-
sions obtained regarding the specific effects of  bifido-
bacteria strains. The studies carried out with the strain 
35624 show that it was effective in reducing the pro-
inflammatory state of  patients with IBD[142,143], as well as 
with UC[144]; besides, the immune modulation effect of  B. 
infantis 35624 was extended to systemic level since it was 
effective in reducing inflammatory biomarkers in patients 
with non-gastrointestinal inflammatory processes, such 
as chronic fatigue syndrome and psoriasis[144]. Most bifi-
dobacteria strains were tested in combination with other 
probiotics (lactobacilli and propionibacteria) and/or 
food-starter bacteria (Streptococcus thermophilus, Lactobacillus 
delbrueckii subsp. bulgaricus and Lactococcus lactis) (Table 2); 
thus, the reported beneficial effects cannot be exclusively 
assigned to a specific bifidobacterial strain. Indeed, the 
two strains of  B. breve included in the table were tested 
together with some of  these bacteria[139,141], or even with 
prebiotics such as galacto-oligosaccharides[140]. In the case 
of  B. animalis subsp. lactis strains, they were often used 
as bio-ingredients of  yogurt-like fermented milks; thus 
the additional beneficial effect of  this food itself  can-
not be obviated. Nevertheless, most human studies car-
Table 1  Reviews obtained from the search into “probiotics” 
Probiotics Author's conclusions Ref.
Treating acute infectious diarrhea Beneficial effects [109]
Prevention of pediatric antibiotic associated diarrhea Evidence of a protective effect [110]
Treating persistent diarrhea in children Limited evidence [111]
Treatment of Clostridium difficile (C. difficile)-associated colitis in adults Insufficient evidence [112]
Prevention of C. difficile-associated diarrhea in adults and children Moderate quality evidence [113]
Prevention of necrotizing enterocolitis in preterm infants Prevents severe necrotizing enterocolitis [114]
Induction of remission in ulcerative colitis Limited evidence [115]
Treatment and prevention of pouchitis after ileal pouch-anal anastomosis  for 
chronic ulcerative colitis
Probiotic VSL#3 was more effective than placebo [116]
Maintenance of remission in ulcerative colitis Insufficient evidence [117]
Maintenance of remission in Crohn's disease No evidence [118]
Induction of remission in Crohn's disease Insufficient evidence [119]
Prevention of post-operative recurrence of Crohn's disease Insufficient randomized trials [120]
Non-alcoholic fatty liver disease and/or steatohepatitis Lack of randomized clinical trials [121]
Patients with hepatic encephalopathy Need of efficacy demonstration [122]
Treatment of bacterial vaginosis No sufficient evidence [123]
Preventing preterm labour Insufficient data [124]
For prevention of allergic disease and food hypersensitivity (in infants) Insufficient evidence [125]
Treating eczema No effective treatment [126]
Preventing acute upper respiratory tract infections Limited evidence [127]
Reviews obtained from the search into “probiotics” in the Cochrane Library (http://onlinelibrary.wiley.com/cochranelibrary/search) of the Cochrane 
Database of Systematic Reviews journal.
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ried out with this species, mainly with the strains Bb12, 
DN-173010 and HN019, showed that they are effective 
in reducing IBS symptoms helping to improve the well-
being of  the individuals[131,132,134-137]. Different bifido-
bacteria species (B. animalis subsp. lactis, B. bifidum, or B. 
infantis), mostly combined with St. thermophilus and/or Lb. 
acidophilus, have been shown to be effective in the preven-
tion and treatment of  antibiotic associated diarrhea[129,130], 
as well as in the prevention of  necrotizing enterocolitis 
in children[138,145,146]. Finally, the inflammatory conditions 
of  different IBD types (Crohn´s disease, UC and pou-
chitis) were reduced, to variable extents, after the use of  
bifidobacteria-containing probiotic products. Particularly 
the product VSL#3, which includes three bifidobacteria 
in combination with five lactic acid bacteria, seems to be 
efficient in the reduction of  symptoms, or maintaining 
remission of  IBD in children and adults[147-154].  
Bifidobacteria as probiotic in respiratory pathology
During the last few years, it has been shown that a few 
probiotic strains have a potential role in reducing the 
symptoms of  asthma and other allergic respiratory 
troubles. For instance, a hydrolyzed formula with B. breve 
and a galacto/fructo-oligosaccharide mixture (prebiotics) 
was able to prevent asthma-like symptoms in infants with 
atopic dermatitis[155]. However, one of  the more promis-
ing applications of  probiotic bacteria in respiratory dis-
eases is the use of  some Lactobacillus and Bifidobacterium 
strains in the treatment of  allergic rhinitis. In a double-
blind, randomized, cross-over study, involving 31 adults 
with allergic rhinitis to grass pollen, Perrin and colleagues 
demonstrated that short-term consumption of  Lactoba-
cillus paracasei NCC2461 reduced subjective nasal pruri-
tus, whilst not affecting nasal congestion[156]. Regarding 
Bifidobacterium strains, oral administration of  B. animalis 
subsp. lactis NCC2818 mitigates immune parameters and 
allergic symptoms in adult subjects suffering from allergic 
rhinitis during seasonal exposure[157]. Also, the strain B. 
longum BB536 has shown promising applications in reliev-
ing symptoms of  cedar pollinosis[158,159]. Furthermore, 
Table 2  Some Bifidobacterium  strains tested in human intervention studies showing positive effects on gastrointestinal functions
Bifido species Bifido strain Other species Reported effect Ref.
B. animalis subs. lactis Bb12 + S. thermophilus Antibiotic associated diarrhoea–children [129]
No Prevent infection in child care centres [130]
+ L. rhamnosus (GG and Lc705), 
P. freudenreichii ssp. shermani JS
Alleviate symptoms of IBS [131]
DN-173010 + S. thermophilus, L. delbureckii subsp. 
bulgaricus, L. lactis (= fermented milk)
Improve symptoms of IBS [132,133]
Improve GI well-being in women with minor 
digestive symptoms
[134,135]
 Affect brain activity (emotion and sensation) in 
healthy women
[136]
HN019 No  Improve functional GI symptoms in adults [137]
B. bifidum NCDO 1453 + L. acidophilus NCDO 1748  Prevent NEC in very low birth weight preterm 
infants
[138]
B. breve Bb99 + L. rhamnosus (GG and Lc705), 
P. freudenreichii ssp. shermani JS
Alleviate symptoms of IBS [139]
Yakult + prebiotic GOS Improve clinical conditions of patients with UC [140]
+ L. casei Shirota Improve symptoms and decrease H2 production in 
lactose-intolerant patients
[141]
B. infantis 35624 No  Alleviate symptoms of IBS [142]
No  Relive symptoms of IBS in woman [143]
No  Reduce systemic pro-inflammatory biomarkers in 
GI and no-GI conditions
[144]
Infloran® (B. infantis) Unknown + L. acidophilus Prevent NEC in very low birth weight preterm 
infants
[145]
ABC Dophilus (B. infantis, 
B. bifidus)
Unknown + S. thermophilus Prevent NEC in very low birth weight neonates [146]
VSL#3® (B. breve, 
B. infantis, B. longum)
Unknown + S. thermophilus, L. acidophilus, 
L. plantarum, L. paracasei,
L. delbrueckii subsp. bulgaricus
Remission of UC in children [147]
Ameliorate symptoms in children with IBS [148]
Reduce symptoms in mild to moderate UC patients [149,150]
Maintain remission in recurrent or refractory 
pouchitis
[151,152]
Reduce the pouchitis activity index in IPAA 
patients
[153]
Reduce the incidence of AAD in risk hospital 
inpatients
[154]
AAD: Antibiotic associated diarrhoea; GI: Gastrointestinal; IBS: Irritable bowel syndrome; IPAA: Ileal pouch anal anastomosis; NEC: Necrotizing 
enterocolitis; UC: Ulcerative colitis; S. thermophilus: Streptococcus thermophilus; L. rhamnosus: Lactobacillus rhamnosus; L. delbureckii: Lactobacillus delbrueckii; 
L. lactis: Lactococcus lactis; L. acidophilus: Lactobacillus acidophilus; L. casei: Lactobacillus casei; L. plantarum: Lactobacillus plantarum; L. paracasei: Lactobacillus 
paracasei; P. freudenreichii: Propionibacterium freudenreichii; B. animalis: Bifidobacterium animalis; B. bifidum: Bifidobacterium bifidum; B. breve: Bifidobacterium breve; 
B. infantis: Bifidobacterium infantis; B. longum: Bifidobacterium longum.
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a combination of  probiotics, including one strain of  L. 
acidophilus and two strains of  B. animalis subsp. lactis, was 
shown to be associated with changes in faecal microbiota 
composition and was able to prevent the pollen-induced 
infiltration of  eosinophils into the nasal mucosa in birch 
pollen allergy, and indicated a trend for reduced nasal 
symptoms[160].
CONCLUSION
The human gut is colonised by a myriad of  microor-
ganisms commonly referred to as intestinal microbiota. 
This complex and dynamic bacterial community plays 
an important role in human health. Alterations, or dys-
bioses, in microbiota composition and function have 
been related to different intestinal and extra-intestinal 
diseases. Among human gut microbiota members the 
genus Bifidobacterium has attracted lot of  scientific inter-
est. Alterations in intestinal bifidobacteria levels, or spe-
cies composition, are often present in cases of  intestinal 
microbiota dysbiosis. Indeed, deviations in intestinal 
bifidobacteria have been observed in different diseases, 
including allergies, IBD, IBS or CRC. Therefore, modu-
lating the intestinal bifidobacteria population has often 
been considered a target for dietary interventions, pro-
viding the rational for the use of  microorganisms of  the 
genus Bifidobacterium as probiotics. Different strains have 
been assessed as probiotics for different diseases, with 
different results obtained depending on both the strain 
and the disease tested. Nevertheless, some Bifidobacterium 
strains have shown very promising results, improving 
IBD, IBS, diarrhoea, and allergy symptoms.
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